This demonstrates a clear need to investigate the relationship between tumour heterogeneity, PARP expression and radiolabelled PARP inhibitors to aid in the accurate diagnosis of PARP expression on PET imaging and optimisation of radionuclide therapy based on PARP radiopharmaceuticals. The gene discussed is PARP1; the disease is neoplasm.